Roche, Meiji and Fedora join forces to tackle increasing bacterial resistance to antibiotics
- Roche licenses investigational beta-lactamase inhibitor OP0595
- OP0595 targets beta-lactamase enzymes in combination with new or existing beta-lactam antibiotics to enhance their effectiveness in difficult-to-treat bacterial infections
Roche (SIX: RO, ROG; OTCQX: RHHBY), Meiji Seika Pharma (Meiji) and Fedora announced today that they have entered into a license agreement for the development and commercialization of OP0595, a beta-lactamase inhibitor (BLI) in phase I clinical development. Under the agreement, Roche obtains worldwide rights from both companies for development and commercialization with the exception of Japan, where Meiji will retain sole commercialization rights. BLIs restore and/or potentiate the activity of beta-lactam antibiotics. The combination of OP0595 with a beta-lactam antibiotic targets severe infections caused by Enterobacteriaceae, including multi-drug-resistant (MDR) strains.